IBCA 9.80 Intervest Bancshares $IBCA Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
IBCA 9.80 Intervest Bancshares $IBCA Hit a 52 week high of 9.80 Closing the day 09:42 at 9.80 unch unch With a day low of 9.78 and a total volume of 4,455.

IBCA Recent Posts: http://investorshangout.com/Intervest-Bancshares-IBCA-54401/

IBCA Intervest Bancshares Recent Headline News

Intervest Bancshares Shares Up 26.3% Since SmarTrend's Buy Recommendation (IBCA)
Comtex SmarTrend(R) - Thu Nov 13, 4:44PM CST
SmarTrend identified an Uptrend for Intervest Bancshares (NASDAQ:IBCA) on December 30th, 2013 at $7.78. In approximately 11 months, Intervest Bancshares has returned 26.30% as of today's recent price of $9.82.
IBCA: 9.79 (-0.01)

Shares of IBCA Up 25.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Nov 06, 11:04AM CST
SmarTrend identified an Uptrend for Intervest Bancshares (NASDAQ:IBCA) on December 30th, 2013 at $7.78. In approximately 10 months, Intervest Bancshares has returned 25.40% as of today's recent price of $9.75.
IBCA: 9.79 (-0.01)

25.4% Return Seen to Date on SmarTrend Intervest Bancshares Call (IBCA)
Comtex SmarTrend(R) - Thu Oct 30, 9:40AM CDT
SmarTrend identified an Uptrend for Intervest Bancshares (NASDAQ:IBCA) on December 30th, 2013 at $7.78. In approximately 10 months, Intervest Bancshares has returned 25.40% as of today's recent price of $9.75.
IBCA: 9.79 (-0.01)

Intervest Bancshares EPS of $0.19
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 7:10AM CDT

IBCA: 9.79 (-0.01)

Intervest Bancshares declares $0.05 dividend
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 7:10AM CDT

IBCA: 9.79 (-0.01)

Intervest Bancshares Corporation Reports 2014 Third Quarter Earnings Increase by 62% to $4.2 Million or $0.19 Per Share
Business Wire - Thu Oct 16, 7:00AM CDT
Intervest Bancshares Corporation (IBC) (NASDAQ-GS:IBCA), parent company of Intervest National Bank (INB), today announced that its net earnings available to common stockholders for the third quarter of 2014 (Q3-14) increased 62% to $4.2 million, or $0.19 per share, from $2.6 million, or $0.12 per share, for the third quarter of 2013 (Q3-13). For the first nine months of 2014 (9mths-14), net earnings available to common stockholders increased 49% to $13.8 million, or $0.62 per share, from $9.2 million, or $0.42 per share, for the same period of 2013 (9mths-13).
IBCA: 9.79 (-0.01)

Intervest Bancshares Up 23.6% Since SmarTrend Uptrend Call (IBCA)
Comtex SmarTrend(R) - Wed Oct 08, 11:04AM CDT
SmarTrend identified an Uptrend for Intervest Bancshares (NASDAQ:IBCA) on December 30th, 2013 at $7.78. In approximately 9 months, Intervest Bancshares has returned 23.60% as of today's recent price of $9.61.
IBCA: 9.79 (-0.01)

GRA, IBCA Expected To Be Up Before Next Earnings Releases
M2 - Wed Oct 08, 3:25AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. W R Grace and Co (NYSE:GRA), Intervest Bancshares Corp (NASDAQ:IBCA) are all expected to be Up Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Up Before earnings are released Wednesday:
GRA: 94.41 (-1.38), IBCA: 9.79 (-0.01)

Intervest Bancshares Has Returned 22.8% Since SmarTrend Recommendation (IBCA)
Comtex SmarTrend(R) - Wed Oct 01, 9:44AM CDT
SmarTrend identified an Uptrend for Intervest Bancshares (NASDAQ:IBCA) on December 30th, 2013 at $7.78. In approximately 9 months, Intervest Bancshares has returned 22.83% as of today's recent price of $9.55.
IBCA: 9.79 (-0.01)

ACHN, IBIO, CRAY, IBCA, QLTY, PIY Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Sep 16, 6:08AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Ibio Inc (NYSE:IBIO), Cray Inc (NASDAQ:CRAY), Intervest Bancshares Corp (NASDAQ:IBCA), Quality Distribution Inc (NASDAQ:QLTY), Preferredplus Trust Series Czn 1 (NYSE IY) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
PIY: 25.52 (-0.02), QLTY: 11.86 (+0.15), ACHN: 13.14 (-0.17), IBIO: 1.10 (+0.01), IBCA: 9.79 (-0.01), CRAY: 32.54 (-1.26)

Intervest Bancshares Corporation Announces Repurchase of Outstanding TARP Warrant
Business Wire - Wed Sep 03, 10:52AM CDT
Intervest Bancshares Corporation (the "Company" (Nasdaq:IBCA), the holding company for Intervest National Bank, announced today that it has repurchased the warrant that had been issued to the U.S. Department of the Treasury in connection with the Company's participation in the TARP Capital Purchase Program. The Company paid Treasury $2,892,066 to repurchase the warrant, which has been cancelled. The Company had originally issued the warrant, which permitted Treasury to purchase up to 691,882 shares of the Company's common stock at an exercise price of $5.42 per share, on December 23, 2008. The Company repurchased all of the shares of TARP preferred stock in June and August of 2013. With the repurchase of the warrant, there are no other investments from the Company's participation in TARP that remain outstanding.
IBCA: 9.79 (-0.01)

INVESTOR ALERT - Intervest Bancshares Corp.: The Law Offices of Vincent Wong Investigates the Sale of Intervest Bancshares Corp. to Bank of the Ozarks, Inc. - IBCA
PR Newswire - Mon Aug 18, 4:14PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Intervest Bancshares Corporation (NasdaqGS: IBCA) ("Intervest" in connection with the sale of the Company to Bank of the Ozarks, Inc. (NasdaqGS: OZRK).
IBCA: 9.79 (-0.01), OZRK: 35.39 (-0.48)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sarepta Under Scrutiny: KSF's Investigation Deepens

Updated Category News Views 3

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Continue Reading
Cyngn: A Deep Dive into Its Robust 24-Patent Portfolio

Updated Category News Views 4

Cyngn's Growing Patent Portfolio: A Robust Defense Ah, Cyngn Inc., the hotshot in AI-powered autonomous vehicle tech, is flexing its muscles with a solid 24-patent stash. We're talking about a company that's not messing around, racking these up since they decided to dive head-first into solving the brain-busting problems of the industrial sector. Their strategy? Build and...

Continue Reading
New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 3

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading
Postal Service Defends New Rule Amid Speculation

Updated Category News Views 3

USPS Navigates Election Mail Controversies The U.S. Postal Service has found itself in the eye of a political storm, thanks to the latest Federal Ballot Mail Rule. Led by Postmaster General David Steiner, the USPS is setting the record straight amidst swirling misinformation and skepticism about its recent actions. This is not just a postal service under scrutiny—it's a...

Continue Reading
Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Updated Category News Views 6

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Continue Reading
BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

Updated Category News Views 1

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
TrailBlazer Magazine Snags a Tribune for In-House Design

Updated Category News Views 4

Who Knew? Design Awards Aren't Just for Pretty Pictures TrailBlazer Magazine gets a pat on the back from GDUSA's 2026 Inhouse Design Awards, a nod to top-notch design work. With over 4,000 entries across the board, getting into the top 10 percent is like finding a steakhouse with zero line on a Friday night. Not exactly common, right? Design Worth Cheering For The winning...

Continue Reading
MMRO Achieves URAC AI Accreditation, Ensures Compliance

Updated Category News Views 4

A Milestone in Healthcare AI: MMRO's New Accreditation When AI in healthcare gets an official nod from the big guys like URAC, it's a significant moment. We're talking about Managed Medical Review Organization, Inc. (MMRO), a firm that's just earned the URAC Artificial Intelligence in Health Care Accreditation. Now, this isn't just some rubber stamp; it's a testament to...

Continue Reading
Dimerix Locks Down A$34M Loan: No Shareholder Dilution

Updated Category News Views 2

Dimerix Grabs Non-Dilutive Funds amid Kidney Trials Here we go with Dimerix's latest move, folks. They roped in A$34 million through a cozy get-together with lenders from Australia and the U.S. What's the kicker? This cash won't touch shareholder equity. So, breathe easy, investors. It's a rare feat to pull off non-dilutive funds these days, especially in the biopharma...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming the Narcolepsy Market: Innovations Ahead

Updated Category News Views 166

The Evolving Landscape of the Narcolepsy Market The narcolepsy market is undergoing significant changes as it shifts from merely managing symptoms to developing targeted therapies that tackle the root causes of the disorder. Traditionally, treatments focused on alleviating symptoms, but advancements now emphasize addressing the underlying neurochemical issues, primarily...

Continue Reading
UBS Analysts Share Insights on China Stocks Strategies

Updated Category News Views 242

UBS Analysts Offer Insights on China's Equity Market In a recent discussion, UBS strategists have expressed a level of caution regarding China's equity market as they look into the evolving landscape of 2025. It's noted that local A-share investors appear hesitant to seize buying opportunities, influenced by a myriad of factors that create uncertainty in the market....

Continue Reading
Palisade Bio's Special Meeting Cancellation: What You Need to Know

Updated Category News Views 133

Palisade Bio Cancels Special Meeting of Stockholders Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company making strides in developing innovative treatments for autoimmune, inflammatory, and fibrotic diseases. Recently, the company announced an important decision regarding its special meeting of stockholders. The special meeting, originally...

Continue Reading
Vivendi Reports Impressive 4.5% Revenue Growth in 2024

Updated Category News Views 123

Remarkable Revenue Growth for Vivendi Vivendi has announced an impressive increase in its revenues for the first nine months of 2024, emphasizing strong growth across its core business sectors. The company reported a revenue increase of 4.5% at constant currency and perimeter, compared to the same period in the previous year. This growth showcases the resilience and...

Continue Reading
Revolution in Home Renovation Arrives with Spray-Net Franchise

Updated Category News Views 226

Fresh Approach to Home Makeovers Home remodeling isn’t just about slapping on a new coat of paint anymore. In February 2026, Spray-Net is gearing up to launch in Allen, Texas, shaking things up in the renovation game. This venture represents a leap forward—not only for franchise growth but for homeowners who are sick and tired of traditional, drawn-out renovations....

Continue Reading